Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G(1) Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2

PURPOSE: To evaluate the safety, maximum-tolerated dose (MTD), pharmacokinetics (PKs), pharmacodynamics, and preliminary anticancer activity of ramucirumab (IMC-1121B), a fully human immunoglobulin G(1) monoclonal antibody targeting the vascular endothelial growth factor receptor (VEGFR)-2. PATIENTS...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Spratlin, Jennifer L., Cohen, Roger B., Eadens, Matthew, Gore, Lia, Camidge, D. Ross, Diab, Sami, Leong, Stephen, O'Bryant, Cindy, Chow, Laura Q.M., Serkova, Natalie J., Meropol, Neal J., Lewis, Nancy L., Chiorean, E. Gabriela, Fox, Floyd, Youssoufian, Hagop, Rowinsky, Eric K., Eckhardt, S. Gail
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2010
Schlagworte:
Original Reports
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2834394/
https://ncbi.nlm.nih.gov/pubmed/20048182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.23.7537
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge